Evidence map›Paper›PMID 37015822›Full record

ArticleNeurology2023

Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis.

Juliette Brenner, Sara Mariotto, Anna E M Bastiaansen, Manuela Paunovic, Sergio Ferrari, Daniela Alberti, Marienke A A M de Bruijn, Yvette S Crijnen, Marco W J Schreurs, Rinze F Neuteboom and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Neuroglial markers of damage in autoimmune neurology.Therapeutic advances in neurological disorders · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Juliette BrennerFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.ORCID 0000-0001-5523-4398
Sara MariottoFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Anna E M BastiaansenFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Manuela PaunovicFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Sergio FerrariFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Daniela AlbertiFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Marienke A A M de BruijnFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Yvette S CrijnenFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Marco W J SchreursFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Rinze F NeuteboomFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.ORCID 0000-0001-6136-4981
Jan G M C DamoiseauxFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Juna M de VriesFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands.
Maarten J TitulaerFrom the Department of Neurology (J.B., A.E.M.B., M.P., M.A.A.M.d.B., Y.S.C., R.F.N., J.M.d.V., M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands; Neurology Unit (S.M., S.F., D.A.), Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Department of Immunology (M.W.J.S.), Erasmus University Medical Center, Rotterdam; and Central Diagnostic Laboratory (J.G.M.C.D.), Maastricht UMC+, the Netherlands. m.titulaer@erasmusmc.nl.ORCID 0000-0002-1033-3840
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesDeterminants of disease activity and prognosis are limited in anti-NMDA receptor (NMDAR) encephalitis. Neurofilament light chains (NfL) are markers of axonal damage and have been identified as valuable biomarkers for neurodegenerative and other neuroinflammatory disorders. We aimed to investigate serum NfL levels in patients with anti-NMDAR encephalitis as a biomarker for disease severity and outcome.

methodsIn this retrospective study, NfL values were measured in all available pretreatment serum and paired CSF samples of the nationwide anti-NMDAR encephalitis cohort. The values were analyzed in duplicate using single-molecule array and compared with measurements in healthy references. Follow-up sera were tested to analyze longitudinal responsiveness, if at least available from 2 time points after diagnosis. Serum NfL levels were compared with data on disease activity (seizures, MRI, and CSF findings), severity (modified Rankin Scale [mRS] score, admission days, and intensive care unit admission), and outcome (mRS score and relapses), using regression analysis.

resultsWe have included 71 patients (75% female; mean age 31.4 years, range 0-85 years) of whom pretreatment serum samples were analyzed. Paired CSF samples were available of 33 patients, follow-up serum samples of 20 patients. Serum NfL levels at diagnosis were higher in patients (mean 19.5 pg/mL, 95% CI 13.7-27.7) than in references (mean 6.4 pg/mL, 95% CI 5.8-7.2, DISCUSSION: Increased serum NfL levels reflect neuroaxonal damage in anti-NMDAR encephalitis. No relationship was identified with disease severity, whereas the association with outcome was confounded by age. The implied role of sampling timing on NfL levels also limits the applicability of NfL as a prognostic marker.

Indexed as

Anti-N-Methyl-D-Aspartate Receptor EncephalitisAdolescentAdultAgedAged, 80 and overBiomarkersChildChild, PreschoolFemaleHumansInfantInfant, NewbornIntermediate FilamentsMaleMiddle AgedNeoplasm Recurrence, LocalBiomarkersNeurofilament Proteins

Identifiers

PMID37015822
PMCPMC10238162
OpenAlexW4362594998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.